Skip to main content

copanlisib

Generic: COPANLISIB DIHYDROCHLORIDE·Brand: ALIQOPA, Aliqopa

copanlisib: 4 clinical trials tracked.

copanlisib evidence translation

What we can confirm

4 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about copanlisib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence8 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (4)

A Phase Ib/II Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer

NCT04253262Registry updated 2025-05-04·Phase 1/Phase 2

Primary endpoint: Maximum Tolerated Dose

Interventionalopen13 targetStarted 2020-04Completion 2027-012 sites · United StatesBrown University

A Phase I Study of PI3Kα,δ Inhibitor Copanlisib in Combination With PD-1 Antagonist Nivolumab in Patients With Transformed Chronic Lymphocytic Leukemia (Richter's Transformation) or Non-Hodgkin Lymphoma

NCT03884998Registry updated 2026-08-21·Phase 1
Active, not recruiting

Primary endpoint: Incidence of dose-limiting toxicities of copanlisib in combination with nivolumab

Interventionalopen27 enrolledStarted 2019-07Completion 2026-113 sites · United StatesCity of Hope Medical Center

Phase Ib Study of Copanlisib in Combination With Nivolumab or With Nivolumab and Ipilimumab

NCT03502733Registry updated 2026-02-20·Phase 1
Active, not recruiting

Primary endpoint: Recommended phase 2 dose of copanlisib and nivolumab combination

Interventionalopen64 targetStarted 2018-08Completion 2026-073 sites · United StatesNational Cancer Institute (NCI)

Molecular Analysis for Therapy Choice (MATCH)

NCT02465060Registry updated 2026-02-27·Phase 2
Active, not recruiting

Primary endpoint: Objective response rate (ORR)

Interventionalopen6,452 targetStarted 2015-08Completion 2026-1250 sites · United StatesNational Cancer Institute (NCI)